Cidara Therapeutics (CDTX) Competitors $13.09 +0.09 (+0.69%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CDTX vs. NTGN, XFOR, SCYX, AGTC, MGTX, VYGR, AKBA, YSB, KMDA, and TSHAShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Neon Therapeutics (NTGN), X4 Pharmaceuticals (XFOR), SCYNEXIS (SCYX), Applied Genetic Technologies (AGTC), MeiraGTx (MGTX), Voyager Therapeutics (VYGR), Akebia Therapeutics (AKBA), YS Biopharma (YSB), Kamada (KMDA), and Taysha Gene Therapies (TSHA). These companies are all part of the "medical" sector. Cidara Therapeutics vs. Neon Therapeutics X4 Pharmaceuticals SCYNEXIS Applied Genetic Technologies MeiraGTx Voyager Therapeutics Akebia Therapeutics YS Biopharma Kamada Taysha Gene Therapies Cidara Therapeutics (NASDAQ:CDTX) and Neon Therapeutics (NASDAQ:NTGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Does the media prefer CDTX or NTGN? In the previous week, Cidara Therapeutics had 3 more articles in the media than Neon Therapeutics. MarketBeat recorded 3 mentions for Cidara Therapeutics and 0 mentions for Neon Therapeutics. Cidara Therapeutics' average media sentiment score of 0.48 beat Neon Therapeutics' score of 0.00 indicating that Cidara Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cidara Therapeutics Neutral Neon Therapeutics Neutral Do analysts recommend CDTX or NTGN? Cidara Therapeutics currently has a consensus target price of $29.67, indicating a potential upside of 126.64%. Given Cidara Therapeutics' higher possible upside, equities analysts plainly believe Cidara Therapeutics is more favorable than Neon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Neon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is CDTX or NTGN more profitable? Neon Therapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Cidara Therapeutics' return on equity of -109.89% beat Neon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara Therapeutics-289.05% -109.89% -34.82% Neon Therapeutics N/A -199.09%-137.14% Does the MarketBeat Community favor CDTX or NTGN? Cidara Therapeutics received 276 more outperform votes than Neon Therapeutics when rated by MarketBeat users. Likewise, 70.30% of users gave Cidara Therapeutics an outperform vote while only 67.87% of users gave Neon Therapeutics an outperform vote. CompanyUnderperformOutperformCidara TherapeuticsOutperform Votes44570.30% Underperform Votes18829.70% Neon TherapeuticsOutperform Votes16967.87% Underperform Votes8032.13% Which has more volatility and risk, CDTX or NTGN? Cidara Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Neon Therapeutics has a beta of -0.81, suggesting that its stock price is 181% less volatile than the S&P 500. Which has stronger valuation & earnings, CDTX or NTGN? Cidara Therapeutics has higher revenue and earnings than Neon Therapeutics. Neon Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$53.87M1.71-$22.93M-$24.87-0.53Neon TherapeuticsN/AN/A-$79.78M-$2.86-1.07 Do insiders and institutionals hold more shares of CDTX or NTGN? 35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 54.7% of Neon Therapeutics shares are held by institutional investors. 7.6% of Cidara Therapeutics shares are held by company insiders. Comparatively, 38.9% of Neon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryCidara Therapeutics beats Neon Therapeutics on 13 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.13M$3.15B$5.50B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.5311.73114.8315.12Price / Sales1.71397.851,497.30100.87Price / CashN/A149.0039.6834.09Price / Book-7.194.024.665.02Net Income-$22.93M-$42.25M$119.06M$225.46M7 Day Performance3.89%8.04%0.80%0.37%1 Month Performance24.07%8.69%5.65%3.57%1 Year Performance-24.31%32.09%36.75%29.43% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics4.2841 of 5 stars$13.09+0.7%$29.67+126.6%-18.5%$92.13M$53.87M-0.5390Upcoming EarningsNews CoverageNTGNNeon TherapeuticsN/A$3.07flatN/AN/A$88.93MN/A-1.15102XFORX4 Pharmaceuticals4.3033 of 5 stars$0.53+5.0%$3.67+598.4%-30.9%$88.46MN/A6.5680News CoverageSCYXSCYNEXIS1.1769 of 5 stars$1.36-0.4%N/A-25.0%$51.30M$140.14M-1.8860Negative NewsAGTCApplied Genetic Technologies0.0937 of 5 stars$0.39flatN/AN/A$26.62M$320,000.00-0.2783Analyst ForecastNews CoverageMGTXMeiraGTx4.4468 of 5 stars$5.64+1.8%$22.50+298.9%+15.3%$366.04M$14.02M-4.03300VYGRVoyager Therapeutics4.2048 of 5 stars$6.67-2.3%$17.43+161.3%+6.9%$363.72M$250.01M23.82100Upcoming EarningsAnalyst UpgradeAKBAAkebia Therapeutics4.0426 of 5 stars$1.71+3.1%$5.75+235.8%+91.6%$360.04M$194.62M-8.15167Short Interest ↓News CoverageYSBYS Biopharma1.4561 of 5 starsN/A$5.25+∞N/A$344.32M$560.76M0.00773KMDAKamada4.4454 of 5 stars$5.97+4.0%$14.50+142.9%+32.7%$343.16M$142.52M22.11360News CoverageTSHATaysha Gene Therapies1.417 of 5 stars$1.65-2.4%$6.38+286.4%-35.8%$338.15M$15.45M-8.25180News Coverage Related Companies and Tools Related Companies Neon Therapeutics Competitors X4 Pharmaceuticals Competitors SCYNEXIS Competitors Applied Genetic Technologies Competitors MeiraGTx Competitors Voyager Therapeutics Competitors Akebia Therapeutics Competitors YS Biopharma Competitors Kamada Competitors Taysha Gene Therapies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDTX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDTX Stock Alerts